ArticleAmerican journal of cancer research2025
Microwave ablation versus bleomycin-lipiodol emulsion with gelatin sponge embolization for hepatic hemangioma: efficacy and recovery outcomes in a retrospective cohort study.
Article in American journal of cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo compare the efficacy and postoperative recovery outcomes of microwave ablation (MWA) and transcatheter arterial embolization (TAE) using a bleomycin-lipiodol emulsion combined with gelatin sponge particles in the treatment of hepatic hemangioma.
methodsIn this retrospective study, 255 patients with hepatic hemangioma treated between January 2020 and June 2024 were analyzed. Patients were assigned to either the MWA group (n = 135) or the TAE group (n = 120). Evaluated parameters included operative characteristics, liver function changes, recovery metrics, complications, treatment efficacy, quality of life, and patient satisfaction.
resultsMWA resulted in a higher overall efficacy rate compared to TAE (76.30% vs. 61.67%, P = 0.011), but was associated with significantly elevated postoperative alanine aminotransferase (ALT) levels (P < 0.001), indicating greater hepatocellular injury. Although ablation procedures were longer (P = 0.005), they were associated with reduced intraoperative blood loss (P = 0.010). TAE was linked to faster recovery, reflected in shorter hospital stays (P = 0.003). The MWA group experienced fewer overall complications, though hemolysis was uniquely observed in this cohort. The TAE group had higher rates of fever and ischemic events. Both groups showed improved quality of life post-treatment, with the MWA group demonstrating greater gains in physical functioning (P = 0.004). Patient satisfaction was comparable between groups.
conclusionMWA and TAE are both effective treatment options for hepatic hemangioma, each with distinct advantages. MWA offers superior lesion control at the expense of greater hepatic stress, while TAE facilitates quicker recovery with a higher incidence of transient complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.